Inhibition of tumorigenicity by the 5′-untranslated RNA of the human c-myc P0 transcript

Experimental Cell Research

Volumn 288, Issue 1, 2003, Pages 131-142

  Blume, Scott W ^a,b,c   Miller, Donald M ^d   Guarcello, Vincenzo ^e   Shrestha, Kedar ^f   Meng, Zheng ^b   Snyder, Richard C ^a   Grizzle, William E ^c,g   Ruppert, J Michael ^a,b,c   Gartland, G Larry ^c,h   Stockard, Cecil R ^g   Jones Jr , David E ⁱ   Emanuel, Peter D ^a,b,c  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g University of Alabama at Birmingham   (United States)

^h University of Alabama at Birmingham   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

5 Untranslated RNA; Apoptotic susceptibility; C myc; Tumorigenicity

Indexed keywords

MYC PROTEIN;

5' UNTRANSLATED REGION; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ANCHORAGE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE LOCUS; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTO ONCOGENE; RNA SEQUENCE; SCID MOUSE;

EID: 0037811247     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(03)00182-4     Document Type: Article

References (63)

1. Mateyak M.K., Obaya A.J., Adachi S., Sedivy J.M. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 8:1997;1039-1048.
2. Pavelic Z.P., Pavelic L., Lower E.E., Gapany M., Gapany S., Barker E.A., Preisler H.D. c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma. Cancer Res. 52:1992;2597-2602.
3. de Alboran I.M., O'Hagan R.C., Gartner F., Malynn B., Davidson L., Rickert R., Rajewsky K., DePinho R.A., Alt F.W. Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. Immunity. 14:2001;45-55.
4. Showe L.C., Moore R.C., Erikson J., Croce C.M. MYC oncogene involved in a t(8;22) chromosome translocation is not altered in its putative regulatory regions. Proc. Natl. Acad. Sci. USA. 84:1987;2824-2828.
5. Cole M.D., McMahon S.B. The Myc oncoprotein a critical evaluation of transactivation and target gene regulation . Oncogene. 18:1999;2916-2924.
6. Bentley D.L., Groudine M. Novel promoter upstream of the human c-myc gene and regulation of c-myc expression in B-cell lymphomas. Mol. Cell. Biol. 6:1986;3481-3489.
7. Miller T.L., Huzel N.J., Davie J.R., Murphy L.C. C-myc gene chromatin of estrogen receptor positive and negative breast cancer cells. Mol. Cell. Endocrinol. 91:1993;83-89.
8. Pullner A., Mautner J., Albert T., Eick D. Nucleosomal structure of active and inactive c-myc genes. J. Biol. Chem. 271:1996;31452-31457.
9. Hoover R.G., Kaushal V., Lary C., Travis P., Sneed T. c-myc transcription is initiated from P0 in 70% of patients with multiple myeloma. Curr. Top. Microbiol. Immunol. 194:1995;257-264.
10. Lang J.C., Wilkie N.M., Clark A.M., Chudleigh A., Talbot S., Whitelaw B., Frame M.C. Regulatory domains within the P0 promoter of human c-myc. Oncogene. 6:1991;2067-2075.
11. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:1967;365-369.
12. Mathews D.H., Sabina J., Zuker M., Turner D.H. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol. 288:1999;911-940.
13. Boylan M.O., Athanassiou M., Houle B., Wang Y., Zarbl H. Activation of tumor suppressor genes in nontumorigenic revertants of the HeLa cervical carcinoma cell line. Cell Growth Differ. 7:1996;725-735.
14. Shim H., Chun Y.S., Lewis B.C., Dang C.V. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc. Natl. Acad. Sci. USA. 95:1998;1511-1516.
15. Prendergast G.C. Mechanisms of apoptosis by c-Myc. Oncogene. 18:1999;2967-2987.
16. Eischen C.M., Roussel M.F., Korsmeyer S.J., Cleveland J.L. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 21:2001;7653-7662.
17. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res. 15:1987;8125-8148.
18. van der Velden A.W., Thomas A.A. The role of the 5′ untranslated region of an mRNA in translation regulation during development. Int. J. Biochem. Cell Biol. 31:1999;87-106.
19. Stoneley M., Subkhankulova T., Le Quesne J.P., Coldwell M.J., Jopling C.L., Belsham G.J., Willis A.E. Analysis of the c-myc IRES a potential role for cell-type specific trans-acting factors and the nuclear compartment . Nucleic Acids Res. 28:2000;687-694.
20. Carter P.S., Jarquin-Pardo M., De Benedetti A. Differential expression of Myc1 and Myc2 isoforms in cells transformed by eIF4E evidence for internal ribosome repositioning in the human c-myc 5′UTR . Oncogene. 18:1999;4326-4335.
21. Parkin N.T., Sonenberg N. Identification of a protein that binds specifically to RNA from the first exon of c-myc. Oncogene. 4:1989;815-822.
22. Chu E., Takechi T., Jones K.L., Voeller D.M., Copur S.M., Maley G.F., Maley F., Segal S., Allegra C.J. Thymidylate synthase binds to c-myc RNA in human colon cancer cells and in vitro. Mol. Cell. Biol. 15:1995;179-185.
23. Brewer G. Characterization of c-myc 3′ to 5′ mRNA decay activities in an in vitro system. J. Biol. Chem. 273:1998;34770-34774.
24. Wisdom R., Lee W. The protein-coding region of c-myc mRNA contains a sequence that specifies rapid mRNA turnover and induction by protein synthesis inhibitors. Genes Dev. 5:1991;232-243.
25. Bernstein P.L., Herrick D.J., Prokipcak R.D., Ross J. Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant. Genes Dev. 6:1992;642-654.
26. Le Quesne J.P., Stoneley M., Fraser G.A., Willis A.E. Derivation of a structural model for the c-myc IRES. J. Mol. Biol. 310:2001;111-126.
27. Ortega L.G., McCotter M.D., Henry G.L., McCormack S.J., Thomis D.C., Samuel C.E. Mechanism of interferon action. Biochemical and genetic evidence for the intermolecular association of the RNA-dependent protein kinase PKR from human cells. Virology. 215:1996;31-39.
28. Clemens M.J., Elia A. The double-stranded RNA-dependent protein kinase PKR structure and function . J. Interferon Cytokine Res. 17:1997;503-524.
29. Bevilacqua P.C., George C.X., Samuel C.E., Cech T.R. Binding of the protein kinase PKR to RNAs with secondary structure defects role of the tandem A-G mismatch and noncontiguous helixes . Biochemistry. 37:1998;6303-6316.
30. Davis S., Watson J.C. In vitro activation of the interferon-induced, double-stranded RNA-dependent protein kinase PKR by RNA from the 3′ untranslated regions of human alpha-tropomyosin. Proc. Natl. Acad. Sci. USA. 93:1996;508-513.
31. Rastinejad F., Conboy M.J., Rando T.A., Blau H.M. Tumor suppression by RNA from the 3′ untranslated region of alpha-tropomyosin. Cell. 75:1993;1107-1117.
32. Subkhankulova T., Mitchell S.A., Willis A.E. Internal ribosome entry segment-mediated initiation of c-Myc protein synthesis following genotoxic stress. Biochem. J. 359:2001;183-192.
33. Gerlitz G., Jagus R., Elroy-Stein O. Phosphorylation of initiation factor-2 alpha is required for activation of internal translation initiation during cell differentiation. Eur. J. Biochem. 269:2002;2810-2819.
34. Fernandez J., Yaman I., Sarnow P., Snider M.D., Hatzoglou M. Regulation of internal ribosomal entry site-mediated translation by phosphorylation of the translation initiation factor eIF2alpha. J. Biol. Chem. 277:2002;19198-19205.
35. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119-128.
36. Sakamuro D., Eviner V., Elliott K.J., Showe L., White E., Prendergast G.C. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene. 11:1995;2411-2418.
37. Petropoulos C.J., Givol I., Hughes S.H. Comparative analysis of the structure and function of the chicken c-myc and v-myc genes v-myc is a more potent inducer of cell proliferation and apoptosis than c-myc . Oncogene. 12:1996;2611-2621.
38. Chang D.W., Claassen G.F., Hann S.R., Cole M.D. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol. Cell. Biol. 20:2000;4309-4319.
39. Xiao Q., Claassen G., Shi J., Adachi S., Sedivy J., Hann S.R. Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. Genes Dev. 12:1998;3803-3808.
40. Marin M.C., Hsu B., Stephens L.C., Brisbay S., McDonnell T.J. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp. Cell Res. 217:1995;240-247.
41. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:1998;2424-2433.
42. Klein G. Dysregulation of lymphocyte proliferation by chromosomal translocations and sequential genetic changes. Bioessays. 22:2000;414-422.
43. Ge K., Duhadaway J., Sakamuro D., Wechsler-Reya R., Reynolds C., Prendergast G.C. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int. J. Cancer. 85:2000;376-383.
44. Martin S.J., Green D.R. Protease activation during apoptosis death by a thousand cuts? Cell. 82:1995;349-352.
45. Fearnhead H.O., McCurrach M.E., O'Neill J., Zhang K., Lowe S.W., Lazebnik Y.A. Oncogene-dependent apoptosis in extracts from drug-resistant cells. Genes Dev. 11:1997;1266-1276.
46. Armstrong D.K., Isaacs J.T., Ottaviano Y.L., Davidson N.E. Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. Cancer Res. 52:1992;3418-3424.
47. Fukasawa K., Wiener F., Vande Woude G.F., Mai S. Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene. 15:1997;1295-1302.
48. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124:1994;619-626.
49. Valentinis B., Reiss K., Baserga R. Insulin-like growth factor-I-mediated survival from anoikis role of cell aggregation and focal adhesion kinase . J. Cell. Physiol. 176:1998;648-657.
50. Frisch S.M., Ruoslahti E. Integrins and anoikis. Curr. Opin. Cell Biol. 9:1997;701-706.
51. Valentinis B., Morrione A., Peruzzi F., Prisco M., Reiss K., Baserga R. Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion. Oncogene. 18:1999;1827-1836.
52. Resnicoff M., Abraham D., Yutanawiboonchai W., Rotman H.L., Kajstura J., Rubin R., Zoltick P., Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55:1995;2463-2469.
53. Rastinejad F., Blau H.M. Genetic complementation reveals a novel regulatory role for 3′ untranslated regions in growth and differentiation. Cell. 72:1993;903-917.
54. Fan H., Villegas C., Huang A., Wright J.A. Suppression of malignancy by the 3′ untranslated regions of ribonucleotide reductase R1 and R2 messenger RNAs. Cancer Res. 56:1996;4366-4369.
55. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell. 4:1999;199-207.
56. Tirkkonen M., Tanner M., Karhu R., Kallioniemi A., Isola J., Kallioniemi O.P. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer. 21:1998;177-184.
57. Barr L.F., Campbell S.E., Bochner B.S., Dang C.V. Association of the decreased expression of alpha3beta1 integrin with the altered cell environmental interactions and enhanced soft agar cloning ability of c-myc-overexpressing small cell lung cancer cells . Cancer Res. 58:1998;5537-5545.
58. McCormack S.J., Weaver Z., Deming S., Natarajan G., Torri J., Johnson M.D., Liyanage M., Ried T., Dickson R.B. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene. 16:1998;2755-2766.
59. Klein G. Multistep evolution of B-cell-derived tumors in humans and rodents. Gene. 135:1993;189-196.
60. Skorski T., Nieborowska-Skorska M., Campbell K., Iozzo R.V., Zon G., Darzynkiewicz Z., Calabretta B. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J. Exp. Med. 182:1995;1645-1653.
61. Evan G., Littlewood T. A matter of life and cell death. Science. 281:1998;1317-1322.
62. Nesbit C.E., Grove L.E., Yin X., Prochownik E.V. Differential apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins. Cell Growth Differ. 9:1998;731-741.
63. Koo H.M., Gray-Goodrich M., Kohlhagen G., McWilliams M.J., Jeffers M., Vaigro-Wolff A., Alvord W.G., Monks A., Paull K.D., Pommier Y., Vande Woude G.F. The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J. Natl. Cancer Inst. 91:1999;236-244.